303727-31-3
基本信息
2-氯-5-(2-苯基-5-(吡啶-4-基)-1H-咪唑-4-基)苯酚
4-(4-氯-3-羟基苯基)-2-苯基-5-(吡啶-4-基)-1H-咪唑
L-779
CS-1697
L-779450
Raf Kinase Inhibitor IV
2-Chloro-5-[2-Phenyl-5-(4-pyridinyl)-1H-imidazol-4-yl]phenol
2-chloro-5-[2-phenyl-4-(4-pyridinyl)-1H-imidazol-5-yl]phenol
2-chloro-5-(2-phenyl-4-(pyridin-4-yl)-1H-imidazol-5-yl)phenol
2-Chloro-5-(2-phenyl-5-(pyridin-4-yl)-1H-iMidazol-4-yl)phenol
Phenol, 2-chloro-5-[2-phenyl-4-(4-pyridinyl)-1H-iMidazol-5-yl]-
物理化学性质
沸点 | 579.8±50.0 °C(Predicted) |
密度 | 1.335±0.06 g/cm3(Predicted) |
储存条件 | Sealed in dry,2-8°C |
溶解度 | DMSO:44.67(Max Conc. mg/mL);128.44(Max Conc. mM) DMF:30.0(Max Conc. mg/mL);86.26(Max Conc. mM) DMF:PBS (pH 7.2) (1:7):0.12(Max Conc. mg/mL);0.35(Max Conc. mM) Ethanol:2.0(Max Conc. mg/mL);5.75(Max Conc. mM) |
酸度系数(pKa) | 8.09±0.10(Predicted) |
形态 | 粉末 |
颜色 | Light yellow to yellow |
安全数据
危险性符号(GHS) | GHS06 |
警示词 | 危险 |
危险性描述 | H301-H315-H319-H335 |
防范说明 | P280-P301+P310+P330-P304+P340+P312-P305+P351+P338-P337+P313 |
海关编码 | 2933399990 |
4-(4-氯-3-羟基苯基)-2-苯基-5-(吡啶-4-基)-1H-咪唑价格(试剂级)
报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
2024/11/08 | HY-12787 | 4-(4-氯-3-羟基苯基)-2-苯基-5-(吡啶-4-基)-1H-咪唑 L-779450 | 303727-31-3 | 5mg | 650元 |
2024/11/08 | HY-12787 | 4-(4-氯-3-羟基苯基)-2-苯基-5-(吡啶-4-基)-1H-咪唑 L-779450 | 303727-31-3 | 10mM * 1mLin DMSO | 715元 |
2024/11/08 | HY-12787 | 4-(4-氯-3-羟基苯基)-2-苯基-5-(吡啶-4-基)-1H-咪唑 L-779450 | 303727-31-3 | 10mg | 1050元 |
常见问题列表
Target | Value |
B-Raf
(Cell-free assay) | 2.4 nM(Kd) |
B-Raf
(Cell-free assay) | 10 nM |
L-779450 (L-779,450) shows a high degree of specificity towards Raf. The only other tested kinase inhibited is p38MAPK, which has a kinase domain structurally related to Raf. L-779450 inhibits anchorage-independent growth of human tumor lines at doses ranging from 0.3 to 2 μM. The effects of L-779450 (L-779,450) on TRAIL sensitivity are investigated here in melanoma cell lines with high TRAIL sensitivity (A-375 and SK-Mel-147), moderate sensitivity (Mel-HO, SK-Mel-13, and SK-Mel-28), and permanent resistance (MeWo, Mel-2a, and SK-Mel-103), as well as in TRAIL-selected cell lines with acquired resistance (A-375-TS and Mel-HO-TS). Despite only moderate direct effects of L-779450 on apoptosis, it strongly enhances TRAIL-induced apoptosis in sensitive melanoma cells and overrules TRAIL resistance in Mel-2a, SK-Mel-103, A-375-TS, and Mel-HO-TS. At 24 hours, 16-35% apoptosis induction is obtained.